Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) . Sunitinib was the first cancer drug simultaneously approved for two different indications. 5-fluoroindolin-2-one is a important intermediate to Sunitinib, yellow crystalline powder. Purity 99% +, The minimum order quantity is 1kg. Packing size : 1 kg/bottle, 5kg/bottel, special packing is offered.